Clinical Trial Detail

NCT ID NCT02923531
Title Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors X4 Pharmaceuticals
Indications

renal cell carcinoma

Therapies

Nivolumab + X4P-001

Age Groups: senior adult

No variant requirements are available.